Pay in 4 interest-free payments of $5.10 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Around 50% of people discontinue GLP-1 RAs within the first year, yet these drugs offer significant benefits in both type 2 diabetes and obesity
siRNA targeting LRP5 (GGACAGACUCAGAGAGACCAA) was transferred into the BMSCs with the help of Lipofectamine 3000 (Invitrogen, United States), and all operations were carried out under the manufacturers instructions
If your region restricts import, check local customs rules before ordering and confirm cold-chain refrigerated delivery is available to your address
Most patients (83.8%, n=119) were not receiving GLP-1RA therapy prior to their initial HS appointment
For patients undergoing elective procedures, most can continue GLP-1 receptor agonists like Zepbound according to current multi-society guidance
Fellow pharma powerhouse Roche has also jumped into the oral obesity arena with the $2.7 billion acquisition of Carmot Therapeutics in December 2023, giving it access to CT-388 and CT-868, both of which are dual agonists of the GLP-1 and GIP receptors with best-in-class potential for obesity, Roche said at the time
